www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/491

Title: Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer
Authors: Buyse, Marc E.
Thirion, Pierre
Carlson, Robert
Burzykowski, Tomasz
Molenberghs, Geert
Piedbois, Pascal
Keywords: Clinical trials
Surrogate Markers
Issue Date: 2001
Publisher: NATL CANCER INSTITUTE
Citation: Journal of the National Cancer Institute, 93(5). p. 399-401
Abstract: Chen et al.(1) recently argued that the results of phase II trials of new therapeutic regimens for extensive-stage small-cell lung cancer (SCLC) cold be used to predict the statistical power of subsequent phase III trials of the same regimens. Furthermore, they concluded that the median survival of patients on phase II trials was more useful than their response rate to predict the outcome of subsequent phase III trials. We believe, however, that their data call for more prudent conclusions. Phase II trials are typically performed with carefully selected patient populations and have often yielded impressive results that could not be reproduced in phase III trials(2). The results of phase II trials are imprecise because of a limited sample size and are unreliable because of the patient selection and the lack of a control group. The data presented by Chen et al. suggest that the results of phase II trials in SCLC poorly predict the outcomes of patients on phase III trials. The authors find no correlation between the median survival of patients on phase II trials and the median survival of patients on the phase III trials.
URI: http://hdl.handle.net/1942/491
DOI: 10.1093/jnci/93.5.399
ISI #: 000167288500019
ISSN: 0027-8874
Category: A1
Type: Journal Contribution
Validation: ecoom, 2002
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version64.76 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.